Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vertex Pharmaceuticals Inc VRTX

Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and... see more

Recent & Breaking News (NDAQ:VRTX)

Jennifer Schneider Elected to Vertex Board of Directors

Business Wire 3 days ago

Vertex Reports First Quarter 2024 Financial Results

Business Wire 12 days ago

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

Business Wire April 26, 2024

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

PR Newswire April 23, 2024

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Business Wire April 18, 2024

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Business Wire April 10, 2024

Vertex to Announce First Quarter 2024 Financial Results on May 6

Business Wire April 9, 2024

Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Canada NewsWire April 1, 2024

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Business Wire April 1, 2024

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Business Wire March 21, 2024

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older

Business Wire February 23, 2024

Vertex to Participate in Upcoming Investor Conferences

Business Wire February 20, 2024

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Business Wire February 13, 2024

Vertex Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 5, 2024

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis

Business Wire February 5, 2024

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

Business Wire January 30, 2024

Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5

Business Wire January 17, 2024

Vertex Announces US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Business Wire January 16, 2024

Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia

Business Wire January 9, 2024

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Business Wire January 7, 2024